Gilead Sciences Says EC Low-Dose Tablet Expands Indication for Biktarvy for HIV Treatment in Pediatric Populations | Tech Reddy

Gilead Sciences Says EC Low-Dose Tablet Expands Indication for Biktarvy for HIV Treatment in Pediatric Populations | Tech Reddy

by

[ad_1]

MT Newswires 2022

GILEAD SCIENCES, INC. All news about.

GILEAD SCIENCES, INC. Analyst recommendations on.

Sale 2022 26 521 M
–
–
Net income 2022 4 384 M
–
–
Net debt 2022 15,970 m
–
–
P/E ratio 2022 23.7x
Harvest 2022 3.42%
Capitalization 107 B
107 B
–
EV / Sales 2022 4.63x
EV / Sales 2023 4.68x
Number of employees 14,400
Free-Float 99.9%

Chart courtesy of GILEAD SCIENCES, INC.


Duration:

Period:




Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener

Technical Analysis Trends GILEAD SCIENCES, INC.

Short term Medium term A long time
Trends Bullish Bullish Bullish

Evolution of the Income Statement

Sat

Buy in
Average consensus PRIVILEGE
Number of analysts 29
Final closing price $85.21
Average target price $81.29
Spread / Average Target -4.60%


[ad_2]

Source link